Expression of Ezrin in breast cancer and its clinical significance: Its cellular connection cannot be formed, leading to loose cell-cell junctions and promoting tumor cell metastasis. On the other hand, over-expression of Ezrin can act on the PI3 Kinase/AKT cell signaling pathway. In a study of osteosarcoma metastasis, Khanna found that after 24-72 hours of high Ezrin expression in tumor cells within lung tissue, the number of these tumor cells did not change; however, tumor cells with inhibited Ezrin expression could not be detected within 24 hours. This indicates that Ezrin's function through the PI3 Kinase/AKT signaling pathway prevents tumor cell apoptosis and promotes tumor cell metastasis. The study also found that the expression of Ezrin protein correlates with clinical stage and survival time. High Ezrin expression is prone to distant organ metastasis, indicating poor prognosis, which aligns with previous reports. For patients who experienced metastasis or death within 5 years, the positive rate of Ezrin protein expression was significantly higher than those whose disease-free survival time exceeded 5 years (P 0.05). In summary, high expression of Ezrin protein in breast cancer patients is associated with lymph node and distant metastasis, resulting in poor prognosis. Ezrin plays an important physiological role in normal mechanisms. Its expression can inhibit tumor cell apoptosis and enhance the metastatic ability of tumor cells. Although further research is needed to elucidate the mechanism by which Ezrin promotes tumor metastasis, its identification is crucial for distinguishing between benign and malignant breast masses and guiding clinical treatment for breast cancer.